Most Study Participants Were Satisfied With a New Long-Acting Injectable HIV Regimen
A follow-up analysis from LATTE-2 showed that most participants generally favored an injectable HIV regimen to taking daily pills, with many stating that it helped with stigma.
An analysis was presented from 39 in-depth interviews of 27 participants (2 of whom were women) and 12 clinicians of patient experiences with injections. Most rated their satisfaction with getting intramuscular injections every 4 or 8 weeks over at least 32 weeks of treatment as a 5 or 6 on a 6-point scale.
Average age was 37 years and most participants were gay men. Almost all reported some level of side effects with the injected regimen: 82% mild and 17% moderate injection site reactions that included soreness, pain, swelling and nodules usually lasting 1-2 days and at most 7 days. Other side effects included fever, tiredness, headache and rash reported by 4% or fewer people.
Some participants said the injections were simpler and more convenient than daily dosing and helped with their confidentiality. Participants generally preferred the injections to taking daily pills (~80%) and would like to continue on them (~85%). However, some were concerned with the number of clinic visits to get the injections, especially for those injected every 4 weeks.
The 12 clinicians were concerned about the issues that injections may pose in the context of patients missing visits, managing side effects and resistance. More research will be needed to identify who would be good candidates for injected regimens.
D Kerrigan, et al. Experiences with long-acting injectable ART: ... (LATTE-2). 2016 International AIDS Conference, Durban, South Africa. Abstract THAB0204.